Read BPM's highlighted coverage of key topics from January
Every month, Benefits and Pensions Monitor will produce a series of articles on a theme affecting Canadian plan sponsors and institutional investors. In January, we focused on GLP-1s and weight management, as generics are expected to come to market in the near future and cost remains top of mind for many private plans.
Read why Beneva's pharmacist Frances Lehun stresses that pharmaceuticals represent only one piece of the puzzle.
NFP consultant Jeannette Makad outlines why preparing for GLP-1 generics means rethinking the whole weight management playbook.
Medavie's Shane Reid explains why plan sponsors should add a weight management module in their benefits.
Generic Ozempic approval looms. However, big cost cuts might not come until next year, according to AGA's Massimo Nini
